Increased level of low-density lipoproteins cholesterine (CH LDL) in blood plasma in parallel with arterial  hypertension and smoking is a main modified risk factor of cardiovascular diseases development. Its correction lays in the basis of clinical recommendations concerning cardiovascular diseases prevention and treatment, although in real clinical practice only minor part of patients of high and very high cardiovascular risk arrives aimed CH LDL indexes. Nowadays it became possible to use a new lipid lowering drug for hypercholesterinemia correction. That is protease inhibitor evolocumab. It was shown during clinical examinations before, that in patients with primary hyperlipidemia and mixed dyslipidemia addition of evolocumab to lipid lowering therapy by statine or ezetemibe lets additionally decrease the level of CH-LPL at 50-70%, and, what is more important, the risk of arising the cardiovascular events such as myocardial infarction and brain stroke is also significantly decreasing in parallel with CH-LPL decrease. The aim of current review is to show practical physicians the information concerning efficacy and safety of PCSK9 inhibitor evolocumab use in different groups of patients.

Keywords: evolocumab, hypercholesterinemia, low density lipoproteins, myocardial infarction, atherosclerosis